Uncategorized

Home 9 Category: Uncategorized

Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease

by aline | Feb 2, 2023 | Uncategorized

Ribonexus appoints Steven Powell as CEO

by aline | Dec 14, 2022 | Uncategorized

Univercells raises € 44 million in first close of its Series D

by aline | Oct 19, 2022 | Uncategorized

Tridek-One closes a €16 million financing round to develop first-in-class imune checkpoint agonists

by aline | Sep 14, 2022 | Uncategorized

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

by aline | Sep 14, 2022 | Uncategorized

Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022

by aline | Sep 12, 2022 | Uncategorized

« Older Entries

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Uncategorized

Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease

Ribonexus appoints Steven Powell as CEO

Univercells raises € 44 million in first close of its Series D

Tridek-One closes a €16 million financing round to develop first-in-class imune checkpoint agonists

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022

Recent Posts

Recent Comments

AdBio partners is a VC firm with a strong entrepreneurial spirit, specialized in early-stage investment in the most promising life sciences startups in Europe.

Menu

Contact

Follow Us